Spero Therapeutics (SPRO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Spero Therapeutics (SPRO) is Neutral.

The composite score behind that read is -0.08, weighing +0.40 of bullish evidence against -0.26 bearish.

Spero Therapeutics last closed at $1.16, -2.52% on the session.

Against the IVW growth benchmark the position is -3.44% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

16 graded predictions for SPRO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Spero Therapeutics in the 80th percentile on valuation and the 75th percentile on return on equity, where 100 is best.

Spero Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $69.30M.

StockMap tracks Spero Therapeutics as the 268th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Spero Therapeutics ranks 68th of 344 in the group, against a group median of -0.21.